Hypertrophic Cardiomyopathy
Pipeline by Development Stage
Drug Modality Breakdown
Cardiovascular is a $69.4B mature market dominated by anticoagulants and metabolic therapies with stable blockbuster portfolios.
Key Trends
- FXa inhibitors (ELIQUIS, XARELTO) command 62% of market spending, creating limited room for new entrants
- SGLT2 inhibitors gaining traction in heart failure indication, signaling expansion beyond traditional anticoagulation
- Multiple patent cliffs (JANUVIA 2027, OPSUMIT 2029) create near-term revenue vulnerability but reinvestment pressure
Career Verdict
Strong choice for commercial, clinical operations, and device integration roles; limited opportunity for innovative pipeline development given market maturity.
AI-generated market analysis based on FDA, CMS, ClinicalTrials.gov, and hiring data
Market Leaders
| # | Product | Company | Revenue | Share | Stage | Trend | LOE |
|---|---|---|---|---|---|---|---|
| 1 | ELIQUIS (Apixaban) | Bristol Myers Squibb | $18.3B | 26% | Peak | Stable | 15.0yr |
| 2 | JARDIANCE (Empagliflozin) | Boehringer Ingelheim | $8.8B | 13% | Peak | Growing | 8.6yr |
| 3 | XARELTO (Rivaroxaban) | Johnson & Johnson | $6.3B | 9% | Peak | Stable | |
| 4 | FARXIGA (Dapagliflozin) | AstraZeneca | $4.3B | 6% | Peak | Growing | 15.4yr |
| 5 | JANUVIA (Sitagliptin) | Merck & Co. | $4.1B | 6% | LOE_Approaching | Declining | 1.1yr |
Drug Class Breakdown
Mature, stable revenue base
Growing in heart failure and renal indications
Declining as LOE approaches 2027
Stable in heart failure management
Niche pulmonary hypertension market
Career Outlook
StableCardiovascular careers are stable but not expanding; the market is mature, dominated by blockbuster franchises with predictable commercial cycles and patent cliffs. Professionals entering this space should expect strong compensation (Commercial $210K avg, Medical Affairs $201K avg) but limited opportunity to drive breakthrough innovation. Device company roles offer better growth trajectories than pharma, particularly in remote monitoring, diagnostics, and patient engagement technologies.
Breaking In
Target device companies (Abbott, Medtronic) for growth potential; if joining pharma, focus on Commercial or Clinical Operations roles where hiring is active and compensation is competitive.
For Experienced Professionals
Leverage cardiovascular expertise to move into medical device strategy, digital health partnerships, or adjacent therapeutic areas; R&D opportunity is limited and may require lateral moves to access innovation-focused roles.
In-Demand Skills
Best For
Hiring Landscape
Cardiovascular hiring is concentrated in device companies (Abbott 337, Medtronic 317) rather than pharma, reflecting the therapeutic area's reliance on hardware solutions and patient management infrastructure. Pharma hiring (Johnson & Johnson 261, Bristol Myers Squibb 52) is heavily weighted toward Commercial (468 roles) and Clinical Operations (296 roles), with minimal R&D investment (14 roles). Medical device integration and remote patient monitoring expertise are increasingly valued as the market consolidates.
Top Hiring Companies
By Department
Device companies offer more growth opportunities; pharma roles are high-paying but oriented toward mature market execution rather than innovation.
Competitive Landscape
13 companies ranked by most advanced pipeline stage
Trial Timeline
Clinical trial activity over time
Showing 15 of 34 trials with date data
Clinical Trials (35)
Total enrollment: 75,158 patients across 35 trials
Ranolazine for the Treatment of Chest Pain in HCM Patients
Candesartan Effect in Second Stage Arterial Hypertension
ARIA (Atacand Renoprotection In NephropAthy Pt.)
A Pharmacogenomic Study of Candesartan in Heart Failure
Candesartan Effectiveness Study in Pro-B Type Natriuretic Peptides (BNP)
Study to Characterize the Long-term Clinical Experience of Atacand in Hypertensive Children Ages 1 to<11 Years (Hypertension in Pediatrics)
Antihypertensive Efficacy and Safety of Candesartan/HCT 32/12.5 and 32/25 mg in Comparison With Candesartan 32 mg
Atacand Dose Ranging in Hypertensive Pediatric Subjects 1 Year to Less Than 6 Years of Age
Efficacy, Safety, & Pharmacokinetics of Candesartan Cilexetil in Hypertensive Paediatric Subjects 6 to < 17 Years of Age
High Doses of Candesartan Cilexetil on the Reduction of Proteinuria
Candesartan in the Prevention of Relapsing Atrial Fibrillation
Danish Hypertension Prevention Project - DHYPP
TROPHY - Candesartan Cilexetil Long-term Hypertension Prevention Trial
Effect of Eleclazine (GS-6615) on Exercise Capacity in Subjects With Symptomatic Hypertrophic Cardiomyopathy
Impact of Diabetes on Left Ventricular Remodeling
CHANCE - Candesartan in Hypertrophic Cardiomyopathy
A Study of EDG-7500 in Adults With Hypertrophic Cardiomyopathy (CIRRUS-HCM)
Multi-center, Open-label, Single-ascending Dose Study of Safety and Tolerability of TN-201 in Adults With Symptomatic MYBPC3 Mutation-associated HCM
Bioequivalence Study in Healthy Subjects
Evaluation of the Pharmacokinetic Interaction Between Candesartan and Felodipine After Ingestion of a Specific Meal
Biventricular Pacing in Hypertrophic Cardiomyopathy
VIZ ACCESS HCM - Multi-Site Registry
A Study to Assess Health-Related Quality of Life in Patients With Hypertrophic Cardiomyopathy in Japan
Viz HCM (ECG Assist) Utilization Workflow Pilot
Extended ECG Monitoring in HCM Patients
A Prospective Incident Study of Arrhythmias in Hypertrophic Cardiomyopathy
Insertable Cardiac Monitors in Hypertrophic Cardiomyopathy
PRecIsion Medicine in CardiomyopathY
Assessment of Wall Thickness in Hypertrophic Cardiomyopathy
Effects of Angiotensin Converting Enzyme (ACE) Inhibitors Versus Candesartan in Reducing Cardiovascular Events in Primary Treatment of Hypertension
Evaluation of Clinical Signs and Symptoms of Chronic Heart Failure in Patients Treated With Candesartan Cilexetil in Croatia
Atacand (Candesartan) Real Life Study
Compliance of Patients With Essential Hypertension Treated With Candesartan or Candesartan/Hydrochlorothiazide
Candesartan and Candesartan/ Hydrochlorothiazide in the Treatment of Patients With Hypertension and LVH
Evaluation of Atacand® (Candesartan) in Daily Medical Practice
Related Jobs in Cardiovascular
Director, Access and Experience Marketing
Associate Medical Director, Spain
Senior Talent Acquisition Partner (Contractor)
Cardiovascular Account Specialist - U.S. Sales, Phoenix North, AZ
Principal Scientist, Computational Chemistry
Senior Director, FP&A
Phase Legend
Key Insights
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.